Date | Name | Shares | Transaction | Value |
Sep 13, 2024
| Michael S. Cuffe EVP and Chief Clinical Officer |
N/A
| Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
0.00
|
Sep 13, 2024
| Michael S. Cuffe EVP and Chief Clinical Officer |
51,758
| Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $145.24 per share |
7,517,331.92
|
Sep 13, 2024
| Michael S. Cuffe EVP and Chief Clinical Officer |
38,036
| Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $386.43 per share |
14,698,251.48
|
Sep 13, 2024
| Michael S. Cuffe EVP and Chief Clinical Officer |
29,678
| Open market or private sale of non-derivative or derivative security Non-derivative transaction at $385.42 per share |
11,438,494.76
|
May 29, 2024
| William Robert Frist Director |
11,905
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
May 29, 2024
| Thomas Fearn Frist Director |
13,497
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
May 21, 2024
| Kathleen M. Whalen SVP & Chief Ethics Officer |
14,179
| Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $133.53 per share |
1,893,321.87
|
May 21, 2024
| Kathleen M. Whalen SVP & Chief Ethics Officer |
12,494
| Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $101.16 per share |
1,263,893.04
|
May 21, 2024
| Kathleen M. Whalen SVP & Chief Ethics Officer |
N/A
| Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
0.00
|
May 21, 2024
| Kathleen M. Whalen SVP & Chief Ethics Officer |
11,318
| Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $322.86 per share |
3,654,129.48
|
May 21, 2024
| Kathleen M. Whalen SVP & Chief Ethics Officer |
9,454
| Open market or private sale of non-derivative or derivative security Non-derivative transaction at $326.3 per share |
3,084,840.20
|
May 21, 2024
| Kathleen M. Whalen SVP & Chief Ethics Officer |
12,045
| Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
0.00
|
May 14, 2024
| Erol R. Akdamar Group President |
60,497
| Bona fide gift |
0.00
|
May 14, 2024
| Erol R. Akdamar Group President |
N/A
| Bona fide gift |
0.00
|
May 14, 2024
| Jeff E. Cohen SVP-Government Relations |
5,185
| Open market or private sale of non-derivative or derivative security Non-derivative transaction at $313 per share |
1,622,905.00
|
May 9, 2024
| Michael S. Cuffe EVP and Chief Clinical Officer |
N/A
| Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
0.00
|
May 7, 2024
| Kathryn A Torres SVP-Payer Contracting & Align. |
21,475
| Open market or private sale of non-derivative or derivative security Non-derivative transaction at $312 per share |
6,700,200.00
|
May 7, 2024
| Kathryn A Torres SVP-Payer Contracting & Align. |
22,365
| Open market or private sale of non-derivative or derivative security Non-derivative transaction at $312 per share |
6,977,880.00
|
May 2, 2024
| Michael W. Michelson Director |
10,478
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
May 2, 2024
| Robert J. Dennis Director |
25,575
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|